Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.

Chen J, Zhao QW, Shi GM, Wang LR.

J Zhejiang Univ Sci B. 2012 Nov;13(11):875-83. doi: 10.1631/jzus.B1200083. Review.

2.

Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis.

Cui Z, Yin Z, Li X, Wu W, Guan P, Zhou B.

BMC Cancer. 2012 Feb 17;12:71. doi: 10.1186/1471-2407-12-71. Review.

5.

Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M, Scagliotti GV.

Clin Cancer Res. 2007 May 15;13(10):2876-81.

6.

Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.

Han B, Guo Z, Ma Y, Kang S, Wang Y, Wei Q, Wu X.

Int J Clin Exp Pathol. 2015 Apr 1;8(4):4113-9. eCollection 2015.

7.

No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Yuan P, Liu L, Wu C, Zhong R, Yu D, Wu J, Xu Y, Nie S, Miao X, Sun Y, Xu B, Lin D.

Cancer Biol Ther. 2010 Nov 1;10(9):854-9. doi: 10.4161/cbt.10.9.13238. Epub 2010 Nov 1.

PMID:
20814250
8.

Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.

Zhao W, Hu L, Xu J, Shen H, Hu Z, Ma H, Shu Y, Shao Y, Yin Y.

Cancer Chemother Pharmacol. 2013 May;71(5):1287-95. doi: 10.1007/s00280-013-2127-8. Epub 2013 Mar 12.

PMID:
23479135
9.

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ.

J Thorac Oncol. 2012 Jun;7(6):973-81. doi: 10.1097/JTO.0b013e31824fe98c.

10.

DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.

Clin Lung Cancer. 2009 Mar;10(2):118-23. doi: 10.3816/CLC.2009.n.015.

PMID:
19362955
11.

Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.

He C, Duan Z, Li P, Xu Q, Yuan Y.

Anticancer Drugs. 2013 Mar;24(3):300-5. doi: 10.1097/CAD.0b013e32835bd6ce.

PMID:
23211354
12.

A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.

Wei HB, Hu J, Shang LH, Zhang YY, Lu FF, Wei M, Yu Y.

Chin Med J (Engl). 2012 Aug;125(16):2902-7. Review.

PMID:
22932088
13.

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.

Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.

Lung Cancer. 2009 Aug;65(2):230-6. doi: 10.1016/j.lungcan.2008.11.014. Epub 2009 Jan 20.

PMID:
19157633
14.

Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.

Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, Wang L, Zhao N, Hu J, Lu D, Jin L, Li Q, Wang JC.

Clin Cancer Res. 2012 Jul 15;18(14):3972-81. doi: 10.1158/1078-0432.CCR-11-1531. Epub 2012 Jun 15.

15.

Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.

Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, Li M, Ren T, Xia L, Cheng Y, Wang D.

Int J Cancer. 2014 Dec 1;135(11):2687-96. doi: 10.1002/ijc.28892. Epub 2014 Apr 25.

16.

Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.

Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF.

Genet Mol Res. 2014 Mar 31;13(3):7617-25. doi: 10.4238/2014.March.31.13.

17.

Association between DNA repair genes (XPD and XRCC1) polymorphisms and susceptibility to age-related cataract (ARC): a meta-analysis.

Zheng LR, Ma JJ, Zhou DX, An LF, Zhang YQ.

Graefes Arch Clin Exp Ophthalmol. 2014 Aug;252(8):1259-66. doi: 10.1007/s00417-014-2679-2. Epub 2014 Jun 7.

PMID:
24906341
18.

Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer.

Liu L, Wu J, Zhong R, Wu C, Zou L, Yang B, Chen W, Zhu B, Duan S, Yu D, Tan W, Nie S, Lin D, Miao X.

Mol Carcinog. 2013 Dec;52(12):923-31. doi: 10.1002/mc.21942. Epub 2012 Jul 20.

PMID:
22821704
19.

Supplemental Content

Support Center